-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

653A.O2.6 653. Myeloma: Therapy, excluding Transplantation: Immunotherapy

Myeloma: Therapy, excluding Transplantation Program: Oral and Poster Abstracts
Type: Oral
Monday, December 5, 2016: 4:30 PM-6:00 PM
Hall AB (San Diego Convention Center)
Moderators:
Torben Plesner, Professor, Vejle Hospital and University of Southern Denmark and Alfred L. Garfall, MD, University of Pennsylvania
Disclosures:
Plesner: Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding.
4:30 PM

Adam D. Cohen, MD1, Alfred L. Garfall, MD1, Edward A Stadtmauer, MD1, Simon Francis Lacey, PhD, BS2*, Eric Lancaster, MD PhD3*, Dan T. Vogl, MD1, Karen Dengel, BSN, RN4*, David E Ambrose, BS4*, Fang Chen, PhD4*, Gabriela Plesa, PhD4*, Irina Kulikovskaya, PhD4*, Vanessa E Gonzalez, M.B.A4*, Minnal Gupta, MSc4*, Regina M Young, PhD5*, Tenesia Carey4*, Regina Ferthio4*, Brendan M. Weiss, MD1, Celeste Richardson, PhD6*, Randi E. Isaacs, MD6*, J. Joseph Melenhorst, PhD4, Bruce L. Levine, PhD7, Carl H June, MD2 and Michael C. Milone, MD, PhD2

1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
2Center for Cellular Immunotherapies, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
3Department of Neurology, University of Pennsylvania, Philadelphia, PA
4Center for Cellular Immunotherapies, University of Pennsylvania School of Medicine, Philadelphia, PA
5Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
6Novartis Institute for Biomedical Research, Cambridge, MA
7Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA

4:45 PM

Adam D. Cohen, MD1, Rakesh Popat2*, Suzanne Trudel, MD3, Paul G Richardson, MD4, Ed N. Libby III, MD5, Nikoletta Lendvai, MD PhD6, Larry D. Anderson Jr., MD, PhD7, Heather J. Sutherland, MD, PhD8, Stephen DeWall9*, Catherine E Ellis10*, Zangdong He10*, Jolly Mazumdar10*, Catherine Wang10*, Joanna B. Opalinska, MD, PhD11 and Peter M. Voorhees, MD12

1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
2Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom
3Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
4Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Boston, MA
5Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA
6Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
7University of Texas Southwestern Medical Center, Dallas, TX
8BCCA, Vancouver, BC, Canada
9GlaxoSmithKline, Upper Merion, PA
10GlaxoSmithKline, Collegeville, PA
11Oncology, GlaxoSmithKline, Collegeville, PA
12Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

5:00 PM

Saad Z Usmani, MD, FACP1, Hareth Nahi2*, Maria-Victoria Mateos, MD, PhD3, Henk M. Lokhorst, MD, PhD4, Ajai Chari, MD5, Jonathan L. Kaufman, MD6, Philippe Moreau7*, Albert Oriol, MD8*, Torben Plesner, Professor9,10, Lotfi Benboubker, MD, PhD11*, Peter Hellemans, MD12*, Tara Masterson13*, Pamela L Clemens, PhD14*, Tahamtan Ahmadi, MD14*, Kevin Liu15* and Jesús F. San-Miguel16

1Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC
2Karolinska Institutet, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm, Sweden
3University Hospital of Salamanca/IBSAL, Salamanca, Spain
4Department of Hematology, VU University Medical Center, Amsterdam, Netherlands
5Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
6Winship Cancer Institute, Emory University, Atlanta, GA
7Department of Hematology, Nantes University Hospital, Nantes, France
8Institut Català d’Oncologia, HGTiP, Barcelona, Spain
9Department of Hematology, University of Southern Denmark, Center Little Belt, Vejle Hospital, Vejle, Denmark
10Department of Hematology, Vejle Hospital and University of Southern Denmark, Vejle, Denmark
11CHU Tours Hopital Bretonneau, Tours, France
12Janssen Research & Development, Beerse, Belgium
13Janssen Research & Development, Spring House, PA
14Janssen Research & Development, LLC, Spring House, PA
15Janssen Research & Development, LLC, Raritan, NJ
16Clínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain

5:15 PM

Maria-Victoria Mateos, MD, PhD1, Jane Estell, B.Med (Honours), FRACP, FRCPA2*, Wolney Barreto, PhD3*, Paolo Corradini, MD4*, Chang-Ki Min, MD5*, Eva Medvedova, MD6, Ming Qi7*, Jordan Schecter8*, Himal Amin8*, Xiang Qin7*, William Deraedt9*, Tineke Casneuf9*, Christopher Chiu7*, A. Kate Sasser7* and Ajay Nooka, MD, MPH10*

1University Hospital of Salamanca/IBSAL, Salamanca, Spain
2Haematology Department, Concord Cancer Centre, Concord Hospital, Concord, NSW, Australia
3Hospital Santa Marcelina, Sao Paulo, Brazil
4Fondazione IRCCS Instituto Nazionale dei Tumori, Milan, Italy
5Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea, The Republic of
6Oregon Health & Science University, Portland, OR
7Janssen Research & Development, LLC, Spring House, PA
8Janssen Research & Development, LLC, Raritan, NJ
9Janssen Research & Development, Beerse, Belgium
10Winship Cancer Institute, Emory University, Atlanta, GA

5:30 PM

Saad Z Usmani, MD, FACP1, Meletios Dimopoulos2, Andrew Belch3, Darrell White, MD4, Lofti Benboubker5*, Gordon Cook, MD, PhD6, Merav Leiba, MD7*, James Morton, MBBS, BSc(Med), FRACP, FRCPA8*, P. Joy Ho9, Kihyun Kim10*, Naoki Takezako, MD, PhD11, Nushmia Z Khokhar12*, Mary Guckert12*, Kaida Wu, MD, PhD12, Xiang Qin12*, Tineke Casneuf13*, Christopher Chiu, PhD12*, A. Kate Sasser12* and Jesús F. San-Miguel14

1Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC
2National and Kapodistrian University of Athens, Athens, Greece
3Department of Oncology, University of Alberta Cross Cancer Institute, Edmonton, AB, Canada
4QEII Health Sciences Center, Dalhousie University, Halifax, NS, Canada
5Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire (CHRU), Tours, France
6St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds, Leeds, United Kingdom
7Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel
8Icon Cancer Care, South Brisbane, QLD, Australia
9Institute of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia
10Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, The Republic of
11Department of Hematology, National Hospital Organization Disaster Medical Center of Japan, Tachikawa, Japan
12Janssen Research & Development, LLC, Spring House, PA
13Janssen Research & Development, Beerse, Belgium
14Clínica Universidad de Navarra-CIMA, IDISNA, Pamplona, Spain

5:45 PM

Marc S. Raab, MD1, Manik Chatterjee, MD2*, Hartmut Goldschmidt, MD3, Hermine Agis, MD4, Igor Blau5*, Hermann Einsele, MD6, Monika Engelhardt, MD, PhD7, Barbara Ferstl, MD8*, Martin Gramatzki, MD9, Christoph Röllig, MD10*, Katja Weisel, MD11*, Tiantom Jarutat, MD12*, Dominika Weinelt, MD12*, Jan Endell, PhD12*, Rainer Boxhammer, PhD12* and Christian Peschel, MD13

1Dept. Med. V, University Hospital Heidelberg, Heidelberg, Germany
2Department of Internal Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany
3Department of Medicine V, University Hospital Heidelberg and the National Center for Tumor Diseases, Heidelberg, Germany
4Department of Medicine I, University Hospital of Internal Medicine – AKH Wien, Vienna, Austria
5Department of Internal Medicine III, Charité Campus Benjamin Franklin, Berlin, Germany
6Department of Medicine II, University Hospital Würzburg, Würzburg, Germany
7Hematology & Oncology Department, Medical University Hospital, Freiburg, Germany
8Department of Internal Medicine 5 - Hematology and Oncology, Friedrich-Alexander-University Erlangen-Nuernberg, Erlangen, Germany
9Department of Medicine, University Hospital Schleswig-Holstein Division of Stem Cell Transplantation and Immunotherapy, Kiel, Germany
10Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany
11Department of Hematology, Oncology, Immunology, Rheumatology and Pulmonology, University Hospital Tuebingen, Tuebingen, Germany
12MorphoSys AG, Martinsried, Germany
13III. Department of Medicine, Hematology and Medical Oncology, Technical University of Munich, Munich, Germany

*signifies non-member of ASH